IL2 and neoplasm: We observed that patients with sCRS had significant differences in the initial tumor load, platelets, neutrophil count, lymphocyte percentage, white blood cells, monocyte count, CRP, dosage, IL-2, D-dimer, TAG, red blood cells, hemoglobin, and procalcitonin, as compared with patients without sCRS.